Emerging Insights in Diagnosing Recurrent Prostate Cancer in Men with Low PSA Levels
Diagnostic Imaging
OCTOBER 7, 2023
In a recent video interview, Ashesh Jani, M.D., discussed a subset analysis from the SPOTLIGHT trial that examined the utility of the PET PSMA agent flotufolastat F 18 (Posluma) for detecting prostate cancer recurrence in men with low PSA levels lower than 1 ng/mL.
Let's personalize your content